Jethro Holter
Chairman at GENETIC ANALYSIS
Net worth: 196 394 $ as of 31/05/2024
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ronny Hermansen | M | 62 | 10 years | |
| Eilert Aamodt | M | 54 | 3 years | |
| Rune Sørum | M | 68 | 14 years | |
| Rolf Einar Engstad | M | 65 |
Biotec BetaGlucans AS
 Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | - |
| Christina Casèn | F | 64 | 15 years | |
| Olav Lanes | M | 52 |
ArcticZymes AS
 ArcticZymes AS Medical SpecialtiesHealth Technology Part of ArcticZymes Technologies ASA, ArcticZymes AS is a Norwegian company that manufactures diagnostic substances. The company is based in Tromsø, Norway. Jethro Holter has been the CEO of the company since 2015. | 14 years |
| Gerd Nilsen | M | 56 |
ArcticZymes AS
ArcticZymes AS Medical SpecialtiesHealth Technology Part of ArcticZymes Technologies ASA, ArcticZymes AS is a Norwegian company that manufactures diagnostic substances. The company is based in Tromsø, Norway. Jethro Holter has been the CEO of the company since 2015. | 14 years |
| Børge Sørvoll | M | 49 |
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | - |
| Camilla Huse Bondesson | M | 66 | 4 years | |
| Marit Sjo Lorentzen | M | 56 |
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | - |
| Kari Furu | M | 44 | 8 years | |
| Lars Tiller | M | - | 2 years | |
| Dirk Hahneiser | M | 56 | 2 years | |
| Darren Ellis | M | - | 2 years | |
| Michael Akoh | M | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Svein Wilhelm Faye Lien | M | 70 | 7 years | |
| Martin Hunt | M | 66 | - | |
| Volker Wedershoven | M | - | - | |
| Kjersti Grimsrud | F | 63 | 4 years | |
| Richard Stuart Godfrey | M | 58 | - | |
| Arne Reinemo | M | - | - | |
| Inger Rydin | F | 67 | 5 years | |
| Christian Jørgensen | M | 65 | 2 years | |
| Per Matsson | M | 70 | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Norway | 24 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jethro Holter
- Personal Network
